May 04, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie reports $25.8 million net loss in first quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a GAAP net loss of $25.8 million, or $0.76 per share, in the first quarter of 2017, compared with $22.7 million, or $0.85 per share, in the same quarter of 2016.
Operating expenses were reported at $25.4 million, with $10.9 million in research and development expenses and $14.5 million in selling, general and administrative expenses, according to a company press release. Operating expenses totaled $22.1 million in the first quarter of 2016.
The higher operating expenses were attributed to an expanded employee base to support operation growth and commercialization preparatory activities, including manufacturing costs for Rhopressa.
Cash, cash equivalents and investments totaled $207.9 million as of March 31.